Primecap Management Co. CA Has $66.12 Million Stock Holdings in Immunocore Holdings plc (NASDAQ:IMCR)

Primecap Management Co. CA increased its holdings in shares of Immunocore Holdings plc (NASDAQ:IMCR) by 3,841.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,951,070 shares of the company’s stock after purchasing an additional 1,901,570 shares during the quarter. Primecap Management Co. CA owned approximately 3.90% of Immunocore worth $66,122,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Bellevue Group AG increased its position in shares of Immunocore by 4,817.1% in the fourth quarter. Bellevue Group AG now owns 976,054 shares of the company’s stock valued at $66,684,000 after acquiring an additional 956,204 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Immunocore by 10.2% during the 4th quarter. Wellington Management Group LLP now owns 4,312,611 shares of the company’s stock worth $294,638,000 after purchasing an additional 399,201 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in Immunocore by 86.3% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 342,000 shares of the company’s stock valued at $22,230,000 after buying an additional 158,455 shares during the period. SG Americas Securities LLC lifted its position in shares of Immunocore by 1,867.3% in the second quarter. SG Americas Securities LLC now owns 160,358 shares of the company’s stock valued at $5,435,000 after buying an additional 152,207 shares during the last quarter. Finally, Candriam S.C.A. boosted its stake in shares of Immunocore by 65.8% during the 2nd quarter. Candriam S.C.A. now owns 313,423 shares of the company’s stock worth $10,621,000 after acquiring an additional 124,417 shares during the period. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

IMCR has been the topic of a number of research analyst reports. JPMorgan Chase & Co. dropped their price target on Immunocore from $70.00 to $66.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 10th. Barclays decreased their price target on shares of Immunocore from $92.00 to $66.00 and set an “overweight” rating on the stock in a research note on Friday, August 9th. Oppenheimer reaffirmed an “outperform” rating and issued a $89.00 target price (up previously from $87.00) on shares of Immunocore in a research report on Friday, August 9th. HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of Immunocore in a report on Tuesday. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a research note on Monday, September 9th. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, Immunocore has an average rating of “Moderate Buy” and an average target price of $80.40.

Immunocore Stock Up 2.7 %

Shares of NASDAQ IMCR opened at $33.90 on Wednesday. Immunocore Holdings plc has a 52 week low of $32.37 and a 52 week high of $76.98. The stock’s fifty day moving average is $37.14 and its 200 day moving average is $46.90. The company has a debt-to-equity ratio of 1.31, a quick ratio of 5.15 and a current ratio of 5.17. The stock has a market capitalization of $1.70 billion, a P/E ratio of -27.79 and a beta of 0.73.

Immunocore (NASDAQ:IMCR) last issued its earnings results on Thursday, August 8th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.25. The company had revenue of $75.40 million during the quarter, compared to analysts’ expectations of $74.58 million. Immunocore had a negative net margin of 19.16% and a negative return on equity of 14.68%. The business’s revenue for the quarter was up 26.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.37) EPS. Sell-side analysts forecast that Immunocore Holdings plc will post -1.79 earnings per share for the current fiscal year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.